Trial · NCT03104374
Adverse events1,550
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,550
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | DIARRHOEA | Gastrointestinal disorders | Period 1: Upadacitinib 15 mg (ICF to Week 56) | 8 | 211 | 8 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 1: Upadacitinib 30 mg (ICF to Week 56) | 15 | 219 | 18 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 1: Pooled Placebo (ICF to Week 24) | 12 | 212 | 13 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56) | 3 | 79 | 4 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56) | 3 | 90 | 3 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 2: Upadacitinib 15 mg (Week 56 to EOS) | 5 | 167 | 5 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 2: Upadacitinib 30 mg (Week 56 to EOS) | 3 | 165 | 5 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS) | 1 | 69 | 1 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS) | 2 | 77 | 2 |
| other | DIARRHOEA | Gastrointestinal disorders | Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 2 | 4 | 87 | 4 |
| other | NAUSEA | Gastrointestinal disorders | Period 1: Upadacitinib 15 mg (ICF to Week 56) | 8 | 211 | 8 |
| other | NAUSEA | Gastrointestinal disorders | Period 1: Upadacitinib 30 mg (ICF to Week 56) | 12 | 219 | 12 |
| other | NAUSEA | Gastrointestinal disorders | Period 1: Pooled Placebo (ICF to Week 24) | 7 | 212 | 8 |
| other | NAUSEA | Gastrointestinal disorders | Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56) | 0 | 79 | 0 |
| other | NAUSEA | Gastrointestinal disorders | Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56) | 1 | 90 | 1 |
| other | NAUSEA | Gastrointestinal disorders | Period 2: Upadacitinib 15 mg (Week 56 to EOS) | 4 | 167 | 5 |
| other | NAUSEA | Gastrointestinal disorders | Period 2: Upadacitinib 30 mg (Week 56 to EOS) | 10 | 165 | 10 |
| other | NAUSEA | Gastrointestinal disorders | Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS) | 0 | 69 | 0 |
| other | NAUSEA | Gastrointestinal disorders | Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS) | 0 | 77 | 0 |
| other | NAUSEA | Gastrointestinal disorders | Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 2 | 1 | 87 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03104374/events